Immuno-oncology startup iOmx Therapeutics has raised $45m in a series A round that will support the progress of its candidates to proof-of-concept stage.

Merck Ventures, the corporate venturing vehicle for pharmaceutical firm Merck Group, has taken part in a €40m ($45m) series A round for Germany-based cancer therapeutics developer iOmx Therapeutics.

Venture capital firms MPM Capital and Sofinnova Partners co-led the round, which included fellow VC firm Wellington Partners. The funding was raised in July this year, according to a statement by iOmx.

Founded in March 2016, iOmx is developing a pipeline of immune-oncology drugs that will work by targeting immune checkpoints. The…